1351 - 1360 of 8571 Results
Title
Year
-
OPENTitle: Identification and structural characterization of small molecule inhibitors of PINK1Journal Name: Scientific ReportsPublisher: Springer Science and Business Media LLCVol: 14Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41598-024-58285-3Best OA location URL: https://www.nature.com/articles/s41598-024-58285-3.pdfCitation Count: 3
- Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson’s Disease2018OPENTitle: Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson’s DiseaseJournal Name: Cell ReportsPublisher: Elsevier BVVol: 22Issue #: 4Start Page: 930End Page: 940Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.celrep.2017.12.092Best OA location URL: http://www.cell.com/article/S2211124717319290/pdfCitation Count: 456
-
OPENTitle: Tau immunoreactivity in peripheral tissues of human aging and select tauopathiesJournal Name: Neuroscience LettersPublisher: Elsevier BVVol: 696Issue #:Start Page: 132End Page: 139Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neulet.2018.12.031Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/7357994Citation Count: 49
- A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson’s disease2019OPENTitle: A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson’s diseaseJournal Name: Science Translational MedicinePublisher: American Association for the Advancement of Science (AAAS)Vol: 11Issue #: 514Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1126/scitranslmed.aau6870Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/7359409Citation Count: 94
- RETRACTED: ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo2014OPENTitle: RETRACTED: ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In VivoJournal Name: Molecular TherapyPublisher: Elsevier BVVol: 22Issue #: 10Start Page: 1753End Page: 1767Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-saDOI - Digital Object Identifier: 10.1038/mt.2014.129Best OA location URL: http://www.cell.com/article/S1525001616307808/pdfCitation Count: 82
- NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation2022OPENTitle: NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome ActivationJournal Name: International Journal of InflammationPublisher: WileyVol: 2022Issue #:Start Page: 1End Page: 12Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1155/2022/2337363Best OA location URL: https://downloads.hindawi.com/journals/iji/2022/2337363.pdfCitation Count: 6
- Structural parameters are superior to eigenvector centrality in detecting progressive supranuclear palsy with machine learning & multimodal MRI2024OPENTitle: Structural parameters are superior to eigenvector centrality in detecting progressive supranuclear palsy with machine learning & multimodal MRIJournal Name: HeliyonPublisher: Elsevier BVVol: 10Issue #: 15Start Page: e34910End Page: e34910Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1016/j.heliyon.2024.e34910Best OA location URL: https://doi.org/10.1016/j.heliyon.2024.e34910Citation Count: 2
- Protocol for the DeFOG trial: A randomized controlled trial on the effects of smartphone-based, on-demand cueing for freezing of gait in Parkinson's disease2021OPENTitle: Protocol for the DeFOG trial: A randomized controlled trial on the effects of smartphone-based, on-demand cueing for freezing of gait in Parkinson's diseaseJournal Name: Contemporary Clinical Trials CommunicationsPublisher: Elsevier BVVol: 24Issue #:Start Page: 100817End Page: 100817Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.conctc.2021.100817Best OA location URL: https://doi.org/10.1016/j.conctc.2021.100817Citation Count: 20
- Progression of MDS‐UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort2017OPENTitle: Progression of MDS‐UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative CohortJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 5Issue #: 1Start Page: 47End Page: 53Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12553Citation Count: 162
-
RESTRICTEDTitle: The Unified Dyskinesia Rating Scale: Presentation and clinimetric profileJournal Name: Movement DisordersPublisher: WileyVol: 23Issue #: 16Start Page: 2398End Page: 2403Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.22341Citation Count: 231